Provider Type and Quality of Outpatient Cardiovascular Disease Care Insights From the NCDR PINNACLE Registry by Virani, Salim S. et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 1 6 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 8 . 0 1 7Provider Type and Quality of
Outpatient Cardiovascular Disease Care
Insights From the NCDR PINNACLE RegistrySalim S. Virani, MD, PHD,*yzx Thomas M. Maddox, MD, MSC,k{ Paul S. Chan, MD, MSC,#** Fengming Tang, MS,#
Julia M. Akeroyd, MPH,* Samantha A. Risch, BS,yy William J. Oetgen, MD, MBA,yy Anita Deswal, MD, MPH,yz
Biykem Bozkurt, MD, PHD,yz Christie M. Ballantyne, MD,zx Laura A. Petersen, MD, MPH*ABSTRACTFro
Re
Co
Te
Dis
He
Mi
Ca
op
Am
Aff
He
triaBACKGROUND The current number of physicians will not be sufﬁcient to accommodate 30 to 40 million Americans
expected to secure health coverage with Affordable Care Act implementation. One proposed solution is to use advanced
practice providers (APPs) (nurse practitioners and physician assistants).
OBJECTIVES This study sought to determine whether there were clinically meaningful differences in the quality of care
delivered by APPs versus physicians in a national sample of cardiology practices.
METHODS Within the American College of Cardiology’s PINNACLE Registry, we compared quality of coronary artery
disease (CAD), heart failure, and atrial ﬁbrillation care delivered by physicians and APPs for outpatient visits between
January 1, 2012, and December 31, 2012. We performed hierarchical regression adjusting for provider sex; panel size;
duration of participation in registry; and patient’s age, sex, insurance, number of outpatient visits, history of hyperten-
sion, diabetes, myocardial infarction, and percutaneous coronary intervention or coronary artery bypass grafting in the
preceding 12 months.
RESULTS We included 883 providers (716 physicians and 167 APPs) in 41 practices who cared for 459,669 patients.
Mean number of patients seen by APPs (260.7) was lower compared with that seen by physicians (581.2). Compliance
with most CAD, heart failure, and atrial ﬁbrillation measures was comparable, except for a higher rate of smoking
cessation screening and intervention (adjusted rate ratio: 1.14; 95% conﬁdence interval: 1.03 to 1.26) and cardiac
rehabilitation referral (rate ratio: 1.40; 95% conﬁdence interval: 1.16 to 1.70) among CAD patients receiving care from
APPs. Compliance with all eligible CAD measures was low for both (12.1% and 12.2% for APPs and physicians, respec-
tively) with no signiﬁcant difference. Results were consistent when comparing practices with both physicians and APPs
(n ¼ 41) and physician-only practices (n ¼ 49).
CONCLUSIONS Apart from minor differences, a collaborative care delivery model, using both physicians and APPs,
may deliver an overall comparable quality of outpatient cardiovascular care compared with a physician-only model.
(J Am Coll Cardiol 2015;66:1803–12) © 2015 by the American College of Cardiology Foundation.m the *Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services
search and Development Center for Innovations, and Section of Health Services Research, Department of Medicine, Baylor
llege of Medicine, Houston, Texas; ySection of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston,
xas; zSection of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas; xCenter for Cardiovascular
ease Prevention, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas; kVeterans Affairs Eastern Colorado
alth Care System, Denver, Colorado; {Division of Cardiology, University of Colorado Denver, Denver, Colorado; #Saint Luke’s
d America Heart Institute, Kansas City, Missouri; **University of Missouri, Kansas City, Missouri; and the yyAmerican College of
rdiology, Washington, DC. Dr. Virani is supported by a Department of Veterans Affairs Health Services Research and Devel-
ment (HSR&D) Service Career Development Award (09-028); American Heart Association Beginning Grant-in-Aid; and the
erican Diabetes Association Clinical Science and Epidemiology award. Dr. Maddox is supported by a Department of Veterans
airs HSR&D Service Career Development Award (08-021). Dr. Chan receives funding (1R01HL123980) from the National
art, Lung, and Blood Institute. Dr. Deswal has received research support from Novartis as site PI of a multicenter clinical
l. Dr. Ballantyne has received grant/research support (all paid to the institution, not individual) from Abbott Diagnostic,
ABBR EV I A T I ON S
AND ACRONYMS
ACA = Affordable Care Act
ACC = American College of
Cardiology
ACE-I = angiotensin-
converting enzyme inhibitor
AF = atrial ﬁbrillation
APP = advanced practice
practitioner
ARB = angiotensin receptor
blocker
CABG = coronary artery bypass
grafting
CAD = coronary artery disease
CVD = cardiovascular disease
HF = heart failure
MI = myocardial infarction
NPs = nurse practitioners
PAs = physician assistants
PCI = percutaneous coronary
intervention
Amarin, A
Synthelabo
American H
Matinas Bio
to Improve
authors ha
Listen to th
Manuscript
Virani et al. J A C C V O L . 6 6 , N O . 1 6 , 2 0 1 5
Provider Type and Performance Measures Compliance O C T O B E R 2 0 , 2 0 1 5 : 1 8 0 3 – 1 2
1804W ith implementation of theAffordable Care Act (ACA) (1),about 20 million Americans
secured health care coverage between
October 1, 2013 and the early part of 2014
(2). The Congressional Budget Ofﬁce esti-
mates that the number of Americans who
will secure coverage as a result of the ACA
implementation will likely increase to 34
million in 2016 (3). A large number of these
previously uninsured Americans will likely
experience many chronic diseases, including
hypertension, diabetes, and cardiovascular
disease (CVD).SEE PAGE 1813The Association of American Medical Col-
leges estimates that the United States will be
short 45,000 primary care physicians and
45,000 specialists by 2020 and that com-
bined total of 90,000 will jump to >130,000
by 2025, with a shortage of nearly 65,000
specialist physicians (4,5). An aging U.S.population (especially those >65 years of age) with a
high prevalence of chronic diseases could put further
pressure on access to physician providers. Compli-
cating this is the projection that nearly one-third of
all physicians will retire in the next decade (6).
Although it remains debatable (7), full implementa-
tion of the ACA could put pressure on the remaining
physician workforce.
One of the proposed ways to deal with the pro-
jected physician shortage is to allow advanced prac-
tice providers (APPs) (i.e., nurse practitioners [NPs]
and physician assistants [PAs]) to function indepen-
dently. Although this nontraditional but innovative
model of health care delivery has been compared in
studies performed in a primary care setting in single,
academic institutions (8–15), the applicability of those
ﬁndings to an outpatient cardiology practice setting is
not known.
Our aim was to determine whether there were
any clinically meaningful differences in the quality
of CVD care provided by APPs, compared with
care provided by physicians in a national sample ofmgen, Bristol-Myers Squibb, Eli Lilly, Esperion, Merck, Nova
, and Takeda Development Centers of America, National Institu
eart Association; is a consultant to Abbott Diagnostic, Amarin,
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received April 2, 2015; revised manuscript received July 14, 2015cardiology practices. We hypothesized that there
would be no clinically meaningful differences in the
quality of CVD care between patients receiving care
from physicians and those receiving care from APPs.
As a secondary aim, we also determined whether
there were any differences in the quality of care
provided by practices using both physicians and APPs
compared with physician-only practices.
METHODS
COHORT DEVELOPMENT. We used the American
College of Cardiology’s (ACC) National Cardiovascular
Data Registry PINNACLE (Practice Innovation and
Clinical Excellence) registry for the current study.
PINNACLE is a prospective U.S.-based outpatient
cardiac quality improvement registry with voluntary
participation from academic and nonacademic cardi-
ology practices (16–18).
Participation in this initiative is voluntary, with
patient data collected at the point of care for
various cardiovascular conditions, including coro-
nary artery disease (CAD), heart failure (HF), and
atrial ﬁbrillation (AF). Performance metrics for CAD,
HF, and AF are endorsed by the ACC, the American
Heart Association, and/or the American Medical
Association-Physician Consortium for Performance
Improvement. Data in the PINNACLE registry are
directly extracted using algorithms mapped to data
in electronic health records (19–21). Quality control
is ensured by the use of a standard data collection
tool with written deﬁnitions, uniform data entry
and transmission requirements, and data quality
checks (18,22).
STUDY POPULATION. Figure 1 provides a ﬂow dia-
gram of study participants and exclusions. For the
purpose of current analyses, we evaluated CAD, HF,
or AF patients enrolled in the PINNACLE registry with
an outpatient cardiology clinic visit between January
1, 2012 and December 31, 2012 among 92 U.S. prac-
tices. For each patient visit, the National Provider
Identiﬁer number of the treating practitioner was
collected at the point of care. The National Provider
Identiﬁer number was searched within the National
Plan and Provider Enumeration System database tortis, Pﬁzer, Regeneron, Roche Diagnostic, Sanoﬁ-
tes of Health, American Diabetes Association, and
Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme,
helabo; and has a provisional patent for “Biomarkers
y Baylor College of Medicine and Roche. All other
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FIGURE 1 Flow Diagram of Study Participants and Exclusions
659,734 eligible patients with outpatient visits
in 2012
(n=92 practices/1352 providers)
648,909 patients remaining after exclusions
(n=90 practices/1234 providers)
10,825 patients excluded (n=2 practices/118 providers)
10,292 patients seeing providers with missing
credentials (n=0 practices/34 providers)
553 patients seen by providers with less than 20 patients
(n=2 practices/84 providers)
189,240 patients in practices with only
physician providers (n=49 practices/351
providers)
459,669* patients in practices with both
physicians and advanced practice providers
(n=41 practices/883 providers)
43,531 patients seen by advanced practice
providers (n=167 non-physicians)†
416,138 patients seen by physician
providers (n=716 physicians)
Overview of patients and practices included in the analyses. *n for primary analyses; †advanced practice providers comprised 141 nurse practitioners and
26 physician assistants.
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1805identify the provider category (physician or APP) (23).
Each patient was then assigned to either a physician
or an APP (NP or PA). In the case of a patient having
seen >1 provider during the study period, the patient
was assigned to whichever provider they saw more
often during the study interval.
We ﬁrst identiﬁed 659,734 eligible patients
enrolled in the PINNACLE registry with an outpatient
visit in 2012 for CAD, HF, or AF. We then excluded
10,825 patients (10,292 patients seeing providers
with missing credentials and 553 patients seen by
providers with <20 patients). With these exclusions,
our study cohort included 648,909 patients receiv-
ing care in 90 practices with 1,234 providers. Of
these, 459,669 patients (70.8%) were receiving
care in practices with both physicians and APP,
whereas 189,240 patients (29.2%) were receiving
care in physician-only practices. Our primary ana-
lyses compared 43,351 patients receiving care from
APP with 459,669 patients receiving care from phy-
sicians in practices with both physicians and APP.
We also performed secondary analyses comparingpatients receiving care in practices with physicians
and APPs (n ¼ 189,240) with patients receiving care
in physician-only practices (n ¼ 459,669). There were
no patients receiving care in practices with only
advanced practice providers.
OUTCOME AND ANALYSES. Our outcome of interest
included compliance with CAD, HF, or AF measures
among eligible patients as per the ACC/American
Heart Association/Physician Consortium for Perfor-
mance Improvement performance measures (19–21).
For CAD, these measures included beta-blocker
use in CAD patients with prior myocardial infarc-
tion (MI), antiplatelet use, smoking cessation screening
and intervention, cardiac rehabilitation referral, symp-
toms and activity assessment, angiotensin-converting
enzyme inhibitor (ACE-I) or angiotensin receptor
blocker (ARB) use in CAD patients with left ventricular
ejection fraction <40%, lipid-lowering therapy, and
blood pressure assessment. We also evaluated the
proportion of CADpatientsmeeting all eligiblemeasures
among the previously mentioned CAD performance
measures.
TABLE 1 Comparison of Baseline Characteristics Among Patients Who Received Care
From Physicians and Advanced Practice Providers
Patients Seeing
Advanced Practice
Providers
(n ¼ 43,531)
Patients Seeing
Physician
Providers
(n ¼ 416,138) p Value
Age, yrs 70.0  13.1 68.7  13.2 <0.0001
Sex 0.007
Male 24,695 (56.7) 238,879 (57.4)
Female 18,831 (43.3) 177,247 (42.6)
Race <0.0001
White 28,073 (91.3) 251,641 (91.0)
Black 2,057 (6.7) 17,228 (6.2)
Other 626 (2.0) 7,652 (2.8)
Insurance <0.0001
No insurance 3,149 (7.2) 23,863 (5.7)
Private 22,537 (51.8) 214,951 (51.7)
Public 13,073 (30.0) 135,880 (32.7)
Unknown 4,772 (11.0) 41,444 (10.0)
Number of visits in 12 months
before index visit
2.8  2.0 2.0  1.4 <0.0001
Patients with $2 visits in 12 months
before index visit
31,244 (71.8) 216,728 (52.1) <0.0001
Tobacco use (current) <0.0001
No 26,815 (61.6) 298,356 (71.7)
Yes 6,495 (14.9) 64,970 (15.6)
Unknown 10,221 (23.5) 52,812 (12.7)
Diabetes 14,601 (33.5) 122,151 (29.4) <0.001
Hypertension 39,803 (91.4) 379,745 (91.3) 0.201
History of myocardial infarction 16,409 (37.7) 172,525 (41.5) <0.001
Percutaneous coronary intervention
in 12 months before index
visit
9,852 (22.6) 77,251 (18.6) <0.001
Coronary artery bypass grafting in
12 months before index visit
5,632 (12.9) 36,919 (8.9) <0.001
Low-density lipoprotein cholesterol 86.8/35.5 88.8/35.9 <0.001
CHADS2 score $2 (among patients
with atrial ﬁbrillation)
15,855 (87.2) 108,837 (86.3) <0.001
NYHA functional class* <0.001
1 3,998 (55.7) 28,007 (58.1)
2 2,325 (32.4) 15,499 (32.1)
3 782 (10.9) 4,245 (8.8)
4 75 (1.0) 460 (1.0)
Values are mean  SD or n (%). *Among the 55,391 patients with ejection fraction <40% and NYHA data
collected.
CHADS2 score ¼ congestive heart failure, hypertension, age$75 years, diabetes mellitus, stroke; NYHA ¼ New
York Heart Association.
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ARB use, beta-blocker use among patients with left
ventricular ejection fraction <40%, and the use of
both ACE-I or ARB and beta-blocker in patients with
left ventricular ejection fraction <40%. For AF, we
assessed the use of anticoagulation (warfarin, dabi-
gatran, or rivaroxaban) in patients with nonvalvular
AF and CHADS2 score $2. For each measure, patients
were excluded from the denominator for an indi-
vidual performance measure if they had a docu-
mented contraindication to that particular therapy(e.g., beta-blocker use after MI in a patient with
hypotension; patient refusal to take warfarin for AF).
We ﬁrst compared demographic and clinical
characteristics of patients receiving care from phy-
sician and APPs using chi-square statistic or Student
t test for categorical and continuous variables,
respectively. In the primary analyses, we compared
compliance with each of the 8 individual CAD per-
formance measures, and compliance with all eligible
CAD measures between APPs and physician pro-
viders. The unit of analysis was the individual pro-
vider. The numerator for these rates was the total
number of patients seen by a provider (physician or
advanced practice) that met the performance mea-
sure (at any visit over the 12-month study period),
and the denominator was the total number of patients
seen by a provider group eligible for that performance
measure.
To assess the association between provider type
and performance rate, we constructed 3-level (with
patients nested within practitioners and practitioners
nested within clinic sites) hierarchical models,
adjusted for provider sex; provider panel size in 2012;
duration of participation in PINNACLE registry; and
patient’s age, sex, insurance, number of outpatient
visits, history of hypertension, diabetes, MI, and
percutaneous coronary intervention (PCI) or coronary
artery bypass grafting (CABG) in the preceding 12
months. These variables were chosen for the adjust-
ment to account for provider (sex) or patient charac-
teristics (insurance status) shown in previous studies
(24–26) to be associated with quality of CVD care,
characteristics that would allow more opportunities
for a provider to work on risk factor modiﬁcation in a
CVD patient (e.g., a lower panel size, more frequent
patient visits) (27), or patient characteristics that
would increase a patient’s complexity or illness
burden (e.g., history of concomitant hypertension,
diabetes, MI, or a history of PCI or CABG in the pre-
ceding 12 months). Modiﬁed Poisson models were
used to estimate rate ratio (28,29). For these analyses,
the physician provider category was used as the
referent category. The resultant rate ratios, therefore,
can be interpreted as the rate of compliance with a
performance measure among APPs divided by the
rate of compliance with a performance measure
among physician providers adjusting for practice
characteristics; provider sex; provider panel size in
2012; duration of participation in PINNACLE registry;
and patient’s age, sex, insurance, number of outpa-
tient visits, history of hypertension, diabetes, MI, and
PCI or CABG in the preceding 12 months. A rate ratio
>1 would signify a higher performance on a perfor-
mance measure by APPs compared with physician
TABLE 2 Comparison of Baseline Characteristics Among
Physicians and Advanced Practice Providers
Advanced Practice
Providers
(n ¼ 167)
Physician
Providers
(n ¼ 716) p Value
Sex <0.0001
Male 17 (10.2) 654 (91.3)
Female 150 (89.8) 62 (8.7)
Number of patients in
provider panel in
2012
260.7  268.6 581.2  348.5 <0.0001
Number of months
participating in the
PINNACLE registry
19.4  12.1 20.7  12.3 0.239
Values are n (%) or mean  SD.
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formed for the HF and AF measures.
We also performed secondary analyses comparing
compliance with CAD, HF, or AF measures among
practices with both physicians and APPs (41 practices
with 459,669 patients) and practices with physician-
only providers (49 practices with 189,240 patients).
These analyses were performed at the level of indi-
vidual practice. The resultant rate ratios can be inter-
preted as the rate of compliance with a performance
measure among practices with both physician and
APPs divided by the rate of compliance with a perfor-
mance measure among practices with physician-only
providers adjusted for provider sex; provider panel
size in 2012; duration of participation in PINNACLE
registry; and patient’s age, sex, insurance, number of
outpatient visits, history of hypertension, diabetes,TABLE 3 Comparison of Compliance With Coronary Artery Disease M
Advanced Practice Providers and Physicians
P
Advanced
Provi
(n ¼
(N ¼ 38
Beta-blocker use in CAD patients with prior MI 81.5 
Antiplatelet use in CAD patients 81.1 
Smoking cessation (screening and intervention) in CAD patients 45.6 
Cardiac rehabilitation referral in CAD patients 11.8 
Symptom and activity assessment in CAD patients 31.4 
ACE-I/ARB in CAD patients with LVEF <40% 76.5 
Lipid-lowering in CAD patients 80.9 
Blood pressure assessment in CAD patients 97.1 
All above CAD performance measures met in eligible patients 12.1 
Values are mean  SD. *Rate ratio ¼ rate for compliance with a performance measure
among physician providers. †Adjusted for practice, provider sex, number of patients in pr
visits, patient’s age, sex, insurance, history of diabetes, hypertension, myocardial infarct
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker
ventricular ejection fraction; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary inMI, and PCI or CABG in the preceding 12 months. All
analyses were performed using SAS version 9.3 (SAS
Institute, Cary, North Carolina).
RESULTS
Our primary analyses (Figure 1) included 459,669 pa-
tients receiving care in practices with both physician
and APPs (17.5% in Northeast, 32.6% in Midwest, 36%
in South, and 13.9% in West). Of these patients, a total
of 416,138 patients were receiving care from 716
physicians and 43,531 patients were receiving care
from 167 APPs (141 NPs, 26 PAs). The number of pa-
tients with CAD, HF, or AF was 414,403, 137,747, and
144,311, respectively.
Baseline characteristics of patients receiving care
from physician and APPs are shown in Table 1. Pa-
tients receiving care from APPs were slightly older,
more often of female sex and African American race,
more likely to have no insurance, and had a higher
prevalence of diabetes. They were less likely to use
tobacco and had a lower prevalence of MI, history of
recent PCI or CABG, or CHADS2 score $2 (among AF
patients) compared with patients receiving care from
physician providers. Patients receiving care from
APPs had a lower number of visits in the 12 months
before their index visit. Although most of these dif-
ferences were statistically signiﬁcant given the large
sample size, absolute differences were numerically
small.
Most of the physicians (91.3%) were males as
opposed to APPs (89.8% females [Table 2]). In addi-
tion, physicians had signiﬁcantly larger patient
panel sizes compared with APPs. The duration ofeasures Among Patients Receiving Care From
rovider Category
Rate Ratio*
(Unadjusted;
Physician Providers as
Referent Category)
Rate Ratio†
(Adjusted;
Physician Providers as
Referent Category)
Practice
ders
167)
,096)
Physician
Providers
(n ¼ 636)
(N ¼ 376,307)
15.1 78.8  12.9 1.10 (1.08–1.13) 1.01 (0.94–1.09)
12.3 79.8  12.7 1.04 (1.01–1.07) 1.04 (1.00–1.08)
39.1 43.3  36.4 1.03 (0.85–1.24) 1.14 (1.03–1.26)
14.9 7.2  10.6 1.95 (1.49–2.54) 1.40 (1.16–1.70)
40.2 29.6  38.2 1.58 (0.93–2.67) 1.02 (0.82–1.27)
13.2 73.8  10.4 1.06 (1.03–1.09) 1.00 (0.96–1.04)
11.5 80.0  10.9 1.03 (1.01–1.06) 1.02 (0.98–1.05)
7.2 95.0  15.1 1.04 (1.02–1.06) 0.99 (0.98–1.00)
17.9 12.2  18.0 1.51 (0.94–2.41) 1.06 (0.86–1.31)
among advanced practice providers/rate of compliance with a performance measure
ovider panel in 2012, length of PINNACLE registry participation, number of outpatient
ion, and PCI or CABG in the last 12 months.
; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; LVEF ¼ left
tervention.
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signiﬁcantly different between physicians and APPs.
Comparison of compliance with CAD performance
measures among APPs and physician providers is
described in Table 3, along with the unadjusted and
adjusted rate ratios. Numerically, the performance on
most of these measures was comparable between
physician and APPs. In adjusted analyses, APPs were
more likely to meet the performance measures of
smoking cessation and cardiac rehabilitation referral
among their CAD patients compared with physician
providers. Importantly, compliance with all eligible
CAD measures was low for both provider categories
(12.1% and 12.2% for APPs and physician providers,
respectively), which was not statistically different.
Comparison of compliance with HF and AF mea-
sures is described in Table 4. For HF, there were no
differences in performance measure rates for ACE-I/
ARB and beta-blocker use or both measures among
HF patients. Similarly, anticoagulant agent use
among high-risk AF patients with CHADS2 score $2
(although low for both provider categories) was not
different between the 2 provider types.
We also performed stratiﬁed analyses comparing
the quality of CVD care between physicians and APPs
in states that allowed independent scope of practice
for APPs in 2012 (30,31) and those states that did not
allow independent scope of practice in 2012 (Online
Tables 1 and 2). These results were qualitatively
comparable with the main study results.
We also performed secondary analyses at the
practice level comparing practices with both physi-
cian and APPs with physician-only practices. These
analyses showed that among patients with CADTABLE 4 Comparison of Compliance With Heart Failure and Atrial Fib
Advanced Practice Providers and Physician Providers
Provider Cat
Advanced Practice
Providers
(n ¼ 167)
(N ¼ 17,295)
ACE-I/ARB use in patients with LVEF <40% 83.2  19.1
Beta-blocker use in patients with LVEF <40% 94.9  9.4
Both HF performance measures met 81.2  20.3
Advanced Practice
Providers
(n ¼ 167)
(N ¼ 18,180)
Anticoagulant agent use in AF patients with
CHADS2 score $2
62.9  15.7
Values are mean  SD. *Rate ratio ¼ rate for compliance with a performance measure
among physician providers. †Adjusted for practice, provider sex, number of patients in pr
visits, patient’s age, sex, insurance, history of diabetes, hypertension, myocardial infarct
AF ¼ atrial ﬁbrillation; HF ¼ heart failure; other abbreviations as in Tables 1 and 3.(Table 5) or HF or AF (Table 6), there were no signif-
icant differences in compliance with performance
measures among practices with both physicians and
APPs (41 practices with 459,669 patients) compared
with physician-only practices (49 practices with
189,240 patients).
DISCUSSION
In these analyses from the ACC’s National Cardio-
vascular Data Registry PINNACLE registry, several
observations can be made. First, the quality of
outpatient CVD care measured by compliance with
performance measures by APPs was equivalent to
that of physician providers on most measures, and
was even marginally better for APPs on some CAD
measures. Second, the quality of outpatient CVD
care delivered by practices with both physicians and
APPs was equivalent to that delivered by physician-
only practices. Last, compliance with global CAD
performance measures (i.e., all eligible measures)
was low for both provider categories. It is important
to note that given the large sample size of our study
population, some of the differences that seem to
be statistically signiﬁcant may not be clinically
relevant.
IMPLICATIONS FOR CARE DELIVERY UNDER THE
ACA. Our ﬁndings indicate that a collaborative care
delivery model that uses both physicians and APPs
seems to provide a care quality that is equivalent to
a physician-only model (Central Illustration). This is
important because millions of Americans will access
care under the ACA (1,2). Our results show that the
use of APPs to improve health care access for theserillation Measures Among Patients Receiving Care From
egory
Rate Ratio*
(Unadjusted;
Physician Providers as
Referent Category)
Rate Ratio†
(Adjusted;
Physician Providers as
Referent Category)
Physician
Providers
(n ¼ 636)
(N ¼ 120,452)
81.3  16.1 1.04 (0.99–1.09) 1.01 (0.98–1.04)
94.1  8.5 1.02 (0.99–1.06) 1.00 (0.99–1.02)
79.2  17.4 1.06 (1.01–1.11) 1.01 (0.98–1.04)
Physician
Providers
(n ¼ 636)
(N ¼ 126,131)
Rate Ratio*
(Unadjusted; Physician
Providers as Referent
Category)
Rate Ratio†
(Adjusted; Physician
Providers as Referent
Category)
61.0  15.4 1.04 (0.99–1.10) 0.98 (0.95–1.02)
among advanced practice providers/rate of compliance with a performance measure
ovider panel in 2012, length of PINNACLE registry participation, number of outpatient
ion, and PCI or CABG in the last 12 months.
TABLE 5 Comparison of Compliance With Coronary Artery Disease Performance Measures Between Practices With Both Physician and
Advanced Practice Providers and Physician-Only Practices
Practice Category
Rate Ratio*
(Unadjusted;
Physician-Only Practices
as Referent Category)
Rate Ratio†
(Adjusted)
Physician-Only
Practices
(n ¼ 49)
(351 Providers)
Practices With Both
Physicians and Advanced
Practice Providers
(n ¼ 4)
(883 Providers)
Beta-blocker use in CAD patients with prior MI 77.2  14.1 78.1  10.3 1.05 (0.98–1.13) 1.04 (0.97–1.12)
Antiplatelet use in CAD patients 75.7  17.8 79.4  12.0 1.08 (0.98–1.20) 1.06 (0.96–1.18)
Smoking cessation (screening and intervention)
in CAD patients
46.4  33.7 46.8  33.8 1.05 (0.57–1.92) 0.97 (0.53–1.77)
Cardiac rehabilitation referral in CAD patients 15.9  29.3 8.1  9.4 1.07 (0.39–2.94) 0.88 (0.33–2.37)
Symptom and activity assessment in CAD patients 35.0  43.9 26.4  37.3 0.89 (0.18–4.28) 0.81 (0.17–3.84)
ACE-I/ARB in CAD patients with LVEF <40% 72.6  15.8 73.1  11.0 1.03 (0.95–1.11) 1.01 (0.93–1.09)
Lipid-lowering in CAD patients 80.5  13.4 79.4  9.9 1.01 (0.94–1.08) 0.99 (0.92–1.06)
Blood pressure assessment in CAD patients 97.3  3.8 95.4  13.0 0.96 (0.89–1.04) 0.94 (0.87–1.01)
All above CAD performance measures met
in eligible patients
21.5  30.2 11.9  18.4 0.81 (0.20–3.19) 0.71 (0.19–2.63)
Values are mean  SD. *Rate ratio ¼ rate for compliance with a performance measure among advanced practice providers/rate of compliance with a performance measure
among physician providers. †Adjusted for practice, provider sex, number of patients in provider panel in 2012, length of PINNACLE registry participation, number of outpatient
visits, patient’s age, sex, insurance, history of diabetes, hypertension, myocardial infarction, and PCI or CABG in the last 12 months.
Abbreviations as in Table 3.
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1809Americans is a viable option as far as meeting basic
outpatient CVD performance metrics is concerned. It
is important to note that our results do not apply to
inpatient clinical settings where both complexity and
dynamics of care are likely different from the outpa-
tient setting. It should also be noted that our ﬁndings
apply only to large integrated cardiology practices
that include advanced practice clinicians and are not
generalizable to other settings.
POLICY IMPLICATIONS. Our results also have
health care policy implications. First, there has been a
debate regarding the scope-of-practice laws governing
APPs. Despite calls from the Institute of Medicine (32)
and the Federal Trade Commission (33–35) to address
the scope-of-practice laws (which fall under theTABLE 6 Comparison of Compliance With Heart Failure and Atrial Fib
Physician and Advanced Practice Providers and Physician-Only Practic
Practice C
Physician-Only
Practices
(n ¼ 49)
(351 Providers)
P
Phy
ACE-I/ARB use in patients with LVEF <40% 79.5  13.7
Beta-blocker use in patients with LVEF <40% 90.8  9.5
Both HF measures performance measures met 75.5  15.8
Anticoagulant agent use in AF patients with
CHADS2 score $2
7.7  19.4
Values are mean  SD. *Rate ratio ¼ rate for compliance with a performance measure
among physician providers. †Adjusted for provider sex, number of patients in provider p
patient’s age, sex, insurance, history of diabetes, hypertension, myocardial infarction, an
Abbreviations as in Tables 3 and 4.purview of states), these laws remain restrictive. For
example, currently only 21 states and the District of
Columbia allow advanced practice NPs to indepen-
dently diagnose, treat, and refer patients and pre-
scribe medications without physician supervision.
Seventeen states limit APP independence by allowing
NPs to diagnose and treat but not to prescribe medi-
cations without physician involvement, and 12 states
require physician oversight of NPs at all levels (diag-
nosis, treatment, and medication prescription) (30).
Our results provide objective data to inform these
discussions and should be reassuring that the quality
of uncomplicated outpatient CVD care is at least
equivalent between APPs and physicians even in
states with independent scope-of-practice laws forrillation Performance Measures Between Practices With Both
es
ategory
Rate Ratio*
(Unadjusted;
Physician-Only Practices
as Referent Category)
Rate Ratio†
(Adjusted)
ractices With Both
sicians and Advanced
Practice Providers
(n ¼ 41)
(883 Providers)
81.5  10.1 1.04 (0.98–1.11) 1.02 (0.96–1.09)
93.9  6.2 1.04 (1.00–1.08) 1.02 (0.98–1.07)
78.9  12.0 1.07 (0.99–1.16) 1.04 (0.96–1.13)
61.1  13.5 1.12 (0.91–1.37) 1.09 (0.88–1.35)
among advanced practice clinicians/rate of compliance with a performance measure
anel in 2012, length of PINNACLE registry participation, number of outpatient visits,
d PCI or CABG in the last 12 months.
CENTRAL ILLUSTRATION Provider Type and Performance Measures Compliance: Provider Workforce Planning
After Affordable Care Act Implementation
Advanced Practice Providers
Shortage of
 Physicians
• Greater access to care
• Aging U.S. population
• High prevalence of chronic
  disease
Aging physician workforce
Increasing demand                                                                                            Decreasing supply
Virani, S.S. et al. J Am Coll Cardiol. 2015; 66(16):1803–12.
Determinants of physician shortages and the role of advanced practice providers in cardiovascular disease care delivery.
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1810APPs (albeit, in physician-owned practices), and be-
tween practices with both APPs and physicians
compared with physician-only practices.
Our results may have implications in terms of how
ACA is implemented. Title V of the ACA (pages 1244 to
1500) (1) calls for increasing the supply of the health
care workforce via support from federal grants in ed-
ucation, training, and continuous education activities.
Although Title V broadly calls for an increase in gov-
ernment funding for physicians, PAs, nurses, and NPs,
speciﬁc allocation of funds among these various con-
stituents is not described. Instead, the ACA calls for the
creation of a National Health Care Workforce Com-
mission to guide Congress, the President, states, and
localities by making recommendations on the appro-
priate use of these resources on the basis of research
evaluating effectiveness of various care models. Our
results indicate that potential return on investment
of these funds for training and education of APPs in
addition to physicians will likely expand the network
of clinicians who can meet the expected growing
shortages in the delivery of chronic disease care.
Our ﬁndings that only 1 in 8 patients with CAD
met all eligible CAD measures (whether they received
care from APPs or physicians) is concerning and
has been described in previous published data (36).Because these performance measures were created to
include treatments shown to improve both cardio-
vascular morbidity and mortality, our results high-
light a need to improve global performance on all
eligible measures in patients with CAD.
STUDY LIMITATIONS. These analyses only assessed
one aspect of the quality of care (i.e., effectiveness of
cardiac care delivery). It is quite possible that there
could be differences between physician and APPs
when other domains of quality of care (e.g., safety,
efﬁciency, or patient-centeredness) are assessed.
Our study assessed the outpatient CVD care for pa-
tients receiving care in cardiology practices enrolled
in the PINNACLE registry. These results, therefore,
may not apply to other cardiology or primary care
practices. It is also important to note our results may
not be generalizable to APP-only practices because
there were no practices with only APPs. For some
measures (e.g., aspirin therapy), over-the-counter
use of medications not captured in the patient’s
medical record could have led to an under-
ascertainment. Although we adjusted for several
patient, provider, and practice characteristics to ac-
count for selection bias, there could still be unmea-
sured confounding for which we could not account.
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: The quality
and effectiveness of outpatient care provided through collabo-
ration of physicians with advanced practice providers can be
comparable with that delivered solely by physicians.
TRANSLATIONAL OUTLOOK: Future studies should address
whether other quality domains, such as the safety, efﬁciency, or
patient-centeredness of care, can be enhanced through collab-
oration between physicians and APPs managing chronic comor-
bidities associated with cardiovascular disease.
J A C C V O L . 6 6 , N O . 1 6 , 2 0 1 5 Virani et al.
O C T O B E R 2 0 , 2 0 1 5 : 1 8 0 3 – 1 2 Provider Type and Performance Measures Compliance
1811Last, these analyses do not account for collaboration
between physician and APPs, which can happen in a
practice while taking care of a complex patient.
Indeed, this collaboration is something that would
be desirable as more patients seek access to health
care.
CONCLUSIONS
A collaborative care delivery model using both
physicians and APPs may deliver quality of outpa-
tient CVD care comparable with a physician-only
model. These results have implications for how re-
sources are allocated for cardiovascular care de-
livery as more Americans access care under the ACA.
Only 1 in 10 patients with CAD regardless of the
provider type met all eligible performance mea-
sures. These results highlight a need to improve
global performance on all eligible measures in CAD
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